SCHEMBL3931339

SCHEMBL3931339

COc1ccc(-c2cc3ncnc(NCc4ccc5c(c4)OCO5)c3s2)cc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 11/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
PI4KB Q9UBF8 1/20 0.53
CLK4 Q9HAZ1 6/20 0.52
PDE2A O00408 1/20 0.51
PDE1A P54750 1/20 0.51
PDE1B Q01064 1/20 0.51
PDE1C Q14123 1/20 0.51
STK17B O94768 1/20 0.49
ALDH1A1 P00352 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2D6 P10635 2/20 0.48
CYP2C9 P11712 2/20 0.48
ALOX15 P16050 2/20 0.48
TSHR P16473 2/20 0.48
CYP2C19 P33261 2/20 0.48
HSD17B10 Q99714 2/20 0.48
LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4071087 0.89 PDE5A (0.55) PDE5AMEN1KMT2ACLK4ALDH1A1
SCHEMBL3933107 0.89 PDE5A (0.53) PDE5AMEN1KMT2ACLK4ALDH1A1
SCHEMBL4068337 0.88 PDE5A (0.58) PDE5AMEN1KMT2ACLK4PDE2A
SCHEMBL3928350 0.87 PDE5A (0.64) PDE5AMEN1KMT2ACLK4PDE2A
SCHEMBL4064454 0.87 PDE5A (0.65) PDE5AMEN1KMT2ACLK4PDE2A
SCHEMBL4064304 0.86 PDE5A (0.56) PDE5AMEN1KMT2ACLK4ALDH1A1
SCHEMBL3927050 0.85 PDE5A (0.59) PDE5AMEN1KMT2ACLK4PDE2A
SCHEMBL4068415 0.85 PDE5A (0.57) PDE5AMEN1KMT2ACLK4ALDH1A1
SCHEMBL3927271 0.85 PDE5A (0.67) PDE5AMEN1KMT2ACLK4PDE2A
SCHEMBL4066690 0.85 PDE5A (0.56) PDE5AMEN1KMT2ACLK4PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
WO-2009007422-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 WO disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 PDE5A 1018/4885MEN1 2686/4885KMT2A 2055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.